How to Play This Market's Dark Clouds<br />By Rev Shark<br />RealMoney.com Contributor<br />12/17/2007 8:30 AM EST <br /><br />"The force of the blow depends on the resistance. It is sometimes better not to struggle against temptation. Either fly or yield at once." <br /><br />-- Francis H. Bradley <br /><br />As we kick off a new week it is a sea of red out there with all major indices around the world trading down. The cause of the problems is quite clear: Inflationary pressures are building while economic growth is slowing. <br /><br />The problem isn't just occurring in the U.S., and the idea that the rest of the world will bail us out is questionable. This morning the German Central Bank's December bulletin stated that German economic growth is likely to slow significantly in 2008, while inflationary pressures should stay high because of rising energy and food prices. <br /><br />As the market has struggled to come to grips with the problems that are out there, we have had no shortage of pundits offering advice on how the government should intervene and fix the problems. The thinking is if we just do what these armchair experts advise then the problems will go away quickly. <br /><br />Although these self-proclaimed economic experts are almost comical in their hubris, they are not nearly as dangerous as the Goldilocks crowd, which wants us to believe that there really aren't any problems out there. We are constantly advised by these experts that we should rush to make sure we are heavily invested so we don't miss out. <br /><br />I really have no idea who is right but I do know, without a doubt, that the market is acting very poorly lately. I could try to resist that fact by giving economic advice to Ben Bernanke or by diminishing the things that the market is obviously worried about, but I'm unlikely to make much money doing that. <br /><br />This market is likely to give us a strong relief bounce at some point this week but the bigger picture is as gloomy as I've ever seen it and trying to anticipate when that will lead to a meaningful market bottom is futile. When things are going down there is no edge in fighting that fact. Simply respect the fact that the market is acting poorly and be patient. <br /><br />If you are inclined to play the short-term game then look for counter-trend rallies but avoid the temptation to conclude that just because we bounce that the worst is behind us. <br /><br />The good news for the market is that seasonality favors some upside in the next few weeks. In addition the Fed is still out there looking for ways to shore up sentiment and they may still have an impact if they persist. <br /><br />The best way to avoid being hurt by this market is to simply accept the fact that the action is poor. Giving advice to government and/or being optimistic that things will quickly change are not likely to make you money. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: KONG +11.6%, EMKR +6.3%, HUM +2.0% (reaffirms Y07 estimates)... M&A news: GRP +18.0% (to be acquired by NOV for $58/share), TT +19.6% (IR to acquire TT for approx $47.81/share)... Other news: CYTX +11.3% (reported positive results in potential new approach in reconstructive surgery), LDK +11.3% (announces conclusion of investigation for reporting Q307 results), FRPT +7.3% (long-term needs lessen, but vehicles still sought - USA Today), NVAX +5.0% (announces favorable results from preclinical studies of influenza virus-like particle vaccine), TWB +4.7% (SAC Capital discloses 5.3% stake in SC 13D), MPG +4.1% (Maguire Properties' Chairman plans to bid for company - WSJ), GHDX +3.8% (announces positive results from Oncotype DX study), IRBT +3.5% (cancels Robotic FX contract - Boston Globe), RMBS +3.5% (licenses XDR memory architecture for HDTV chipset), KOSN +3.4% (shows 55% clinical benefit in patients with trastuzumab-refractory metastatic breast cancer ), ULBI +2.8% (awarded $62 mln order), TSL +2.4% (still checking), NILE +2.3% (Cramer makes positive comments on MadMoney), HST +2.0% (announces quarterly and special dividend on common stock). Analyst upgrades: ABK +22.8% (upgraded to Outperform at Friedman Billings), DK +4.2% (upgraded to Buy at Citigroup), GSIC +2.7% (upgraded to Buy at Needham).<br /><br />Allapoole avanevad:<br /><br />In reaction to weak earnings/guidance: IR -6.8% (also plans to acquire TT for approx $47.81/share), KBR -4.9%, ITW -4.3%, SIMO -1.9%... Other news: PPHM -45.7% (Defense threat reduction agency halts contract negotiations with the co as it suffers $100 mln cut), HSOA -19.0% (notes in 8-K that previously issued financial statements for first two quarters of 2007 should not be relied upon), ESLT -5.5% (announces that Skylark II was selected by Korean military), OUTD -4.8% (CFO resigns), ERIC -3.3% (still checking), RTP -3.7% (to invest in Australian coal mine possibly to fight off an unwanted approach from rival BHP Billiton - Reuters), NOV -3.1% (acquiring GRP, expected to be accretive to earnings and cash flow in Y08), ADY -2.9% (shares could fall even further in the coming months - Barron's), ALU -2.7% (still checking), BHP -2.2% (RTP invests in Austrailian coal mine to fight off an unwanted approach from BHP), MT -2.1% (announces it has terminated its agreement with E2 Acquisition for the sale of ArcelorMittal USA's Sparrows Point). Analyst downgrades: PCLN -3.1% (downgraded to Hold at Citigroup), COF -2.5% (downgraded to Sell at Citigroup), CAT -2.3% (downgraded to Underweight at Morgan Stanley), UBS -2.0% (downgraded to Sector Perform at CIBC), CFC -1.5% (downgraded to Hold at Citigroup).